Shinichiro Nakajima1, Fernando Caravaggio2, David C Mamo3, Benoit H Mulsant4, Jun Ku Chung5, Eric Plitman6, Yusuke Iwata7, Philip Gerretsen8, Hiroyuki Uchida9, Takefumi Suzuki10, Wanna Mar11, Alan A Wilson12, Sylvain Houle13, Ariel Graff-Guerrero14. 1. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan. Electronic address: shinichiro.l.nakajima@gmail.com. 2. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: fernando.caravaggio@gmail.com. 3. Department of Psychiatry, Faculties of Medicine and Health Science, University of Malta, Msida, Malta. Electronic address: mamodc@gmail.com. 4. Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Campbell Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. Electronic address: benoit.mulsant@camh.ca. 5. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: junku.chung@mail.utoronto.ca. 6. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: plitmaneric@gmail.com. 7. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan. Electronic address: yusuke.iwata2010@gmail.com. 8. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: philgerretsen@yahoo.com. 9. Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan. Electronic address: hiroyuki.uchida.hu@gmail.com. 10. Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan. Electronic address: takefumi@oak.dti.ne.jp. 11. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada. Electronic address: wanna.mar@camh.ca. 12. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Campbell Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. Electronic address: alan.wilson@camh.ca. 13. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Campbell Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. Electronic address: sylvain.houle@camh.ca. 14. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada; Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Campbell Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. Electronic address: ariel_graff@yahoo.com.mx.
Abstract
BACKGROUND: No study has examined dopamine D₂/₃ receptor (D₂/₃R) availability in antipsychotic-free older patients with schizophrenia. METHODS: We included patients with schizophrenia 50 years or older who were antipsychotic-free for at least 3 months. We compared non-displaceable binding potential (BPND) of [(11)C]-raclopride in the caudate, putamen, ventral striatum, and globus pallidus between patients and age- and sex-matched healthy controls. RESULTS: Ten patients participated (antipsychotic-naive=4). No differences in BPND were found between patients and controls in any ROIs (F(1, 72)=.42, p=.52). CONCLUSION: The preliminary results suggest no differences in D₂/₃R availability between antipsychotic-free older patients with schizophrenia and controls.
BACKGROUND: No study has examined dopamine D₂/₃ receptor (D₂/₃R) availability in antipsychotic-free older patients with schizophrenia. METHODS: We included patients with schizophrenia 50 years or older who were antipsychotic-free for at least 3 months. We compared non-displaceable binding potential (BPND) of [(11)C]-raclopride in the caudate, putamen, ventral striatum, and globus pallidus between patients and age- and sex-matched healthy controls. RESULTS: Ten patients participated (antipsychotic-naive=4). No differences in BPND were found between patients and controls in any ROIs (F(1, 72)=.42, p=.52). CONCLUSION: The preliminary results suggest no differences in D₂/₃R availability between antipsychotic-free older patients with schizophrenia and controls.
Authors: Andri C Tziortzi; Graham E Searle; Sofia Tzimopoulou; Cristian Salinas; John D Beaver; Mark Jenkinson; Marc Laruelle; Eugenii A Rabiner; Roger N Gunn Journal: Neuroimage Date: 2010-06-30 Impact factor: 6.556
Authors: Hiroyuki Uchida; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shitij Kapur Journal: J Clin Psychiatry Date: 2008-12-16 Impact factor: 4.384
Authors: Oliver D Howes; Joseph Kambeitz; Euitae Kim; Daniel Stahl; Mark Slifstein; Anissa Abi-Dargham; Shitij Kapur Journal: Arch Gen Psychiatry Date: 2012-08
Authors: Shinichiro Nakajima; Hiroyuki Uchida; Robert R Bies; Fernando Caravaggio; Takefumi Suzuki; Eric Plitman; Wanna Mar; Philip Gerretsen; Bruce G Pollock; Benoit H Mulsant; David C Mamo; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2015-07-28 Impact factor: 9.306
Authors: Gagan Fervaha; Fernando Caravaggio; David C Mamo; Benoit H Mulsant; Bruce G Pollock; Shinichiro Nakajima; Philip Gerretsen; Tarek K Rajji; Wanna Mar; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Gary Remington; Ariel Graff-Guerrero Journal: Psychopharmacology (Berl) Date: 2016-08-24 Impact factor: 4.530
Authors: Fernando Caravaggio; Gagan Fervaha; Yusuke Iwata; Eric Plitman; Jun Ku Chung; Shinichiro Nakajima; Wanna Mar; Philip Gerretsen; Julia Kim; M Mallar Chakravarty; Benoit Mulsant; Bruce Pollock; David Mamo; Gary Remington; Ariel Graff-Guerrero Journal: Int J Geriatr Psychiatry Date: 2017-11-07 Impact factor: 3.485